Drugs / PI-2620
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07105384 | Feb 2025 → Jun 2028 expected | Parkinson disease | Fundacion Clinic per a la Recerca Biomédica | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04906590 | Aug 2021 → Jan 2023 | Parkinson disease | Michael J. Fox Foundation for Parkinson's Research | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2024-08-28 | AC Immune SA | Regulatory AC Immune’s PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions acimmune.com ↗ |
| 2020-07-07 | AC Immune SA | Results Tau-PET Tracer PI-2620 Could Set New Standards for an Improved Diagnosis of Progressive Supranuclear Palsy acimmune.com ↗
The results indicate that PI-2620 could facilitate an earlier and more reliable diagnosis of PSP, where previous Tau tracers and other biomarkers failed. |
| 2020-04-02 | AC Immune SA | Results AC Immune Presents the Latest Preclinical Data on Novel Drug Targets for Neurodegenerative Diseases acimmune.com ↗
18F-PI-2620 Tau PET is associated with beta-amyloid in MCI or mild-AD dementia subjects from the elenbecestat Mission AD program |
| 2019-03-27 | AC Immune SA | Results New Clinical Data on AC Immune's Novel Next Generation Tau PET-Tracer Presented by Licensing Partner, Life Molecular Imaging, at AD/PD(TM) Conference acimmune.com ↗
New data further support 18 F-PI-2620’s potential as a new PET Tracer for progressive supranuclear palsy (PSP) detection |
| 2018-10-29 | AC Immune SA | Results AC Immune Partner Life Molecular Imaging Presents New Clinical Study Results for Tau PET-Tracer 18F-PI-2620 acimmune.com ↗
The results of the Test-Retest study for 18 F-PI-2620 in AD and non-demented controls (NDC) demonstrated favorable kinetics, high target specificity with low off-target binding and high signal in regions of expected tau pathology. |
| 2017-04-03 | AC Immune SA | Results Piramal Imaging and AC Immune present first clinical data for tau PET-imaging tracer at International Alzheimer's Conference acimmune.com ↗
First results of the ongoing clinical program confirmed the favorable potential of PI-2620. |
All press releases naming this drug 9 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PI-2620 | “Quantification Tools for a Novel Tau PET Marker in a Rare Neurological Disease: 18F-PI-2620 in Progressive Supranuclear Palsy” NCT07105384 ↗ |
| Modality | Diagnostic / imaging agent | “radiopharmaceutical imaging agent” NCT04906590 ↗ |